Author | Matthew Davids, MD | OncLive

Author | Matthew Davids, MD


Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLL

June 16, 2018


Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.

Dr. Matthew Davids On Advances in CLL

February 18, 2015


Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.